Enhanced Spanish Drug Label Study to Promote Patient Understanding and Use
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01200849|
Recruitment Status : Completed
First Posted : September 14, 2010
Last Update Posted : November 18, 2014
|Condition or disease||Intervention/treatment|
|Medication Understanding Diabetes Hypertension||Other: Enhanced Label|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||420 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Enhanced Spanish Drug Label Design to Promote Patient Understanding and Use|
|Study Start Date :||October 2010|
|Primary Completion Date :||January 2013|
|Study Completion Date :||January 2014|
Experimental: Enhanced Label
Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
Other: Enhanced Label
A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
No Intervention: Standard Label
Subjects in this arm will receive their prescriptions labeled with a standard label.
- Understanding of prescription medication [ Time Frame: Baseline, 3 month follow-up, 9 month follow-up ]Difference in understanding and comprehension of medication use as compared to control.
- Change in HbA1c or blood pressure readings [ Time Frame: Baseline, 3 month follow-up, 9 month follow-up ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01200849
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Michael Wolf, Phd, MPH||Northwestern University|